Slide 1: Q3'2022 Results
We engineer enzymes to improve health… of people and the planet Q3’2022 Results November 3, 2022
Slide 2: Forward Looking Statements
Forward Looking Statements • These slides and any accompanying oral presentation contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and
Slide 3: Refreshed Corporate Vision
Refreshed Corporate Vision PERFORMANCE ENZYMES Assessing the markets where Focusing on pharmaceutical our CodeEvolver® platform has manufacturing and life sciences, a clear competitive advantage which represent ~95% of revenue Identifying the most attractive BIOTHERAPEUTICS market opportunities and
Slide 4: Our Most Advanced Biotherapeutics Assets
Our Most Advanced Biotherapeutics Assets CDX-7108 for EPI CDX-6114 for PKU Gene Therapies ▪ Most advanced clinical asset; ▪ Phenylketonuria (PKU) is one of ▪ Use CodeEvolver® to engineer being co-developed 50/50 with the most common inborn errors proteins that may improve Nestlé Health Science of me
Slide 5: Enhanced Commercial Focus
Enhanced Commercial Focus Pharmaceutical Life Sciences Biotherapeutics Manufacturing ▪ Maintain strong relationships ▪ Continue to design and ▪ Prioritize pipeline assets with top global manufacture enzymes as ▪ Clarify investment required pharmaceutical manufacturers stand-alone products to hit val
Slide 6: Q3 2022 Results
Q3 2022 Results $34M $28M Q3’22 Total Q3’22 Product Revenue -6% Revenue -2% $31.1M $3.3M 65% $109M Performance Biotherapeutics Gross Product Margin Cash as of Enzymes vs. 76% in Q3’21 9/30/2022. No Debt $22M $13M $10M R&D Expense SG&A Expense Net Loss 6
Slide 7: Q3 2022 Segment Financials
Q3 2022 Segment Financials Performance Enzymes Biotherapeutics $31.1M $3.3M Q3’22 Revenue Q3’22 Revenue $10.8M ($11.4M) Q3’22 Income Q3’22 Loss from from Operations1 Operations1 Supported by $9.4M of corporate overhead expense (not allocated to either business segment) 1 Represents total revenues by
Slide 8: 2022 Guidance
2022 Guidance $135-141M $112-118M 65-70% Total Revenue Product Revenue Product Gross Margin Cash Runway Through the end of 2024 8
Slide 9: Nasdaq: CDXS www.codexis.com
Nasdaq: CDXS www.codexis.com